BICYCLE THERAPEUTICS plc
For the period ended Dec 31, 2023. Filed Feb 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 20, 2024
BCYC$3.77+4.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| | | |
|---|---|---|
| · Page | ||
| Special Note Regarding Forward Looking Statements | | i |
| | | |
| | | |
| PART I | | |
| | | |
| Item 1. Business | | 2 |
| | | |
| Item 1A. Risk Factors | | 46 |
| | | |
| Item 1B. Unresolved Staff Comments | | 106 |
| | | |
| Item 1C. Cybersecurity | | 106 |
| | | |
| Item 2. Properties | | 107 |
| | | |
| Item 3. Legal Proceedings | | 108 |
| | | |
| Item 4. Mine Safety Disclosures | | 108 |
| | | |
| PART II | | |
| | | |
| Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | | 109 |
| | | |
| Item 6. [Reserved] | | 109 |
| | | |
| Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations | | 110 |
| | | |
| Item 7A. Quantitative and Qualitative Disclosures About Market Risk | | 127 |
| | | |
| Item 8. Financial Statements and Supplementary Data | | 128 |
| | | |
| Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | | 128 |
| | | |
| Item 9A. Controls and Procedures | | 128 |
| | | |
| Item 9B. Other Information | | 130 |
| | | |
| Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections | | 130 |
| | | |
| PART III | | |
| | | |
| Item 10. Directors, Executive Officers and Corporate Governance | | 130 |
| | | |
| Item 11. Executive Compensation | | 131 |
| | | |
| Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | | 131 |
| | | |
| Item 13. Certain Relationships and Related Transactions, and Director Independence | | 131 |
| | | |
| Item 14. Principal Accountant Fees and Services | | 131 |
| | | |
| PART IV | | |
| | | |
| Item 15. Exhibit and Financial Statement Schedules | | 132 |
| | | |
| | | |
| Signatures | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.